US genomics giant Illumina acquired cancer detection company while $8 billion deal was under review
The European Commission has opened an investigation into actions taken by the US-based genomics company Illumina, after the company announced it had acquired a cancer detection company without waiting for EU approval.
It comes as genetic testing and tailoring of medical treatments to a person’s individual genetic profile is gaining increasing importance for the treatment of diseases with genetic factors, including cancer.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.